Methylscopolamine bromide
Clinical data
Trade namesPamine, Extendryl, AlleRx, Rescon
ATC code
Pharmacokinetic data
Elimination half-life3–4 hrs
  • (1R,2S,4R,5S,7R)-{[(2R)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[,4]nonane
CAS Number
PubChem CID
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.005.314 Edit this at Wikidata
Chemical and physical data
Molar mass318.388 g/mol (398.297 g/mol with bromide) g·mol−1
3D model (JSmol)
  • OC[C@H](c1ccccc1)C(=O)O[C@H]2C[C@@H]3[N+](C)(C)[C@H](C2)[C@H]4O[C@@H]34
  • InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1 checkY

Methylscopolamine or methscopolamine, usually provided as the bromide or nitrate salt, is an oral medication used along with other medications to treat peptic ulcers by reducing stomach acid secretion.[1] Proton pump inhibitors and antihistamine medications have made this use obsolete. It can also be used for stomach or intestinal spasms, to reduce salivation, and to treat motion sickness. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications[2]

Methscopolamine, a methylated derivative of scopolamine, is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine. Its mechanism of action involves blocking the muscarinic acetylcholine receptors.

It was patented in 1902 and approved for medical use in 1947.[3] Methscopolamine is an FDA-approved analog to hyoscine butylbromide.

Brand names

Brand names include Extendryl, AlleRx, Rescon, Pamine.


  1. ^ Methscopolamine
  2. ^ Gennaro AR. The Science and Practice of Pharmacy. Remington. pp. 402–403, 1025. ISBN 0912734043.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 446. ISBN 9783527607495.